小児固形腫瘍の化学療法における rhG-CSF の有用性

概要

論文の詳細を見る
The purpose of this study was to confirm whether the administration of rhG-CSF could shorten the period of neutropenia induced by chemotherapy. RhG-CSF was given to one child with hepatoblastoma and two children with neuroblastoma after intensive chemotherapy. The same chemotherapeutic regimens were repeated in 3 to 4 weeks interval. On the third day after the chemotherapy, subcutaneous bolus injection of rhG-CSF was started and was continued daily for 10 days. All patients received the same dose of rhG-CSF. The absolute neutrophil counts were taken and the effects of rhG-CSF were compared between control cycles and rhG-CSF treated cycles. The number of neutrophils started to rise about one week after initiating rhG-CSF injection. The increase in peripheral nutrophils was maintained as long as the injection of rhG-CSF was continued. After stopping rhG-CSF injeciton, the number of neutrophils returned to the control level within 2 to 8 days. In most cycles with treatment of rhG-CSF, it was observed that the duration of neutropenia was shorter and the recovery of neutrophils was more rapid than control cycles. Elevations of nadirs, however, were not marked. In 86% of rhG-CSF cycles, chemotherapy was completed on schedule. The results of this study suggested that the administration of rhG-CSF after chemotherapy reduces the duration of neutropenia and is useful for accomplishment of chemotherapy on schedule. However, the effects of rhG-CSF was not obvious when bone marrow hypoplasia due to prolonged chemotherapy was severe. However, rhG-CSF will be a promising agent of adjuvant therapy in chemotherapy for pediatric malignant solid neoplasm, more studies are necessary to determine the optimal dose.
1992-10-20

小児固形腫瘍の化学療法における rhG-CSF の有用性

スポンサーリンク

概要

著者

関連論文

スポンサーリンク